Cancer Research UK has announced plans to construct a state-of-the-art cancer R&D facility at the charity's Clare Hall laboratories in Herfordshire, UK. The center will cost an estimated L20.0 million ($40.5 million) and will house the group's Biotherapeutics Development Unit.
Gillian Lewis, the head of the Cancer Research UK's BDU, said: "biotherapeutics really are at the cutting edge in terms of the development of new cancer treatments and, in order to achieve significant advances, we need the best facilities. That's exactly what the new building gives us."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze